Human Mendelian pain disorders: a key to discovery and validation of novel analgesics
Identifieur interne : 001418 ( Main/Exploration ); précédent : 001417; suivant : 001419Human Mendelian pain disorders: a key to discovery and validation of novel analgesics
Auteurs : Yp Goldberg [Canada] ; Sn Pimstone [Canada] ; R. Namdari [Canada] ; N. Price [Canada] ; C. Cohen [Canada] ; Rp Sherrington [Canada] ; Mr Hayden [Canada]Source :
- Clinical Genetics [ 0009-9163 ] ; 2012-10.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Analgesic, Analgesics (metabolism), Analgesics (therapeutic use), Congenital, Drug Discovery (methods), Erythromelalgia, Erythromelalgia (genetics), Genetics, Human, Humans, Mutation (genetics), NAV1.7 Voltage-Gated Sodium Channel (genetics), NAV1.7 Voltage-Gated Sodium Channel (metabolism), Pain, Pain Insensitivity, Congenital (drug therapy), Pain Insensitivity, Congenital (genetics), Test validation, Voltage-Gated Sodium Channel Blockers.
- MESH :
- chemical , genetics : NAV1.7 Voltage-Gated Sodium Channel.
- chemical , metabolism : Analgesics, NAV1.7 Voltage-Gated Sodium Channel.
- chemical , therapeutic use : Analgesics.
- drug therapy : Pain Insensitivity, Congenital.
- genetics : Erythromelalgia, Mutation, Pain Insensitivity, Congenital.
- methods : Drug Discovery.
- Humans, Voltage-Gated Sodium Channel Blockers.
Abstract
We have utilized a novel application of human genetics, illuminating the important role that rare genetic disorders can play in the development of novel drugs that may be of relevance for the treatment of both rare and common diseases. By studying a very rare Mendelian disorder of absent pain perception, congenital indifference to pain, we have defined Nav1.7 (endocded by SCN9A) as a critical and novel target for analgesic development. Strong human validation has emerged with SCN9A gain‐of‐function mutations causing inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder, both Mendelian disorder of spontaneous or easily evoked pain. Furthermore, variations in the Nav1.7 channel also modulate pain perception in healthy subjects as well as in painful conditions such as osteoarthritis and Parkinson disease. On the basis of this, we have developed a novel compound (XEN402) that exhibits potent, voltage‐dependent block of Nav1.7. In a small pilot study, we showed that XEN402 blocks Nav1.7 mediated pain associated with IEM thereby demonstrating the use of rare genetic disorders with mutant target channels as a novel approach to rapid proof‐of‐concept. Our approach underscores the critical role that human genetics can play by illuminating novel and critical pathways pertinent for drug discovery.
Url:
DOI: 10.1111/j.1399-0004.2012.01942.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000917
- to stream Istex, to step Curation: 000917
- to stream Istex, to step Checkpoint: 000265
- to stream PubMed, to step Corpus: 000A17
- to stream PubMed, to step Curation: 000A17
- to stream PubMed, to step Checkpoint: 000A17
- to stream Ncbi, to step Merge: 001210
- to stream Ncbi, to step Curation: 001210
- to stream Ncbi, to step Checkpoint: 001210
- to stream Main, to step Merge: 001450
- to stream PascalFrancis, to step Corpus: 000171
- to stream PascalFrancis, to step Curation: 000A81
- to stream PascalFrancis, to step Checkpoint: 000155
- to stream Main, to step Merge: 001569
- to stream Main, to step Curation: 001418
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human Mendelian pain disorders: a key to discovery and validation of novel analgesics</title><author><name sortKey="Goldberg, Yp" sort="Goldberg, Yp" uniqKey="Goldberg Y" first="Yp" last="Goldberg">Yp Goldberg</name></author><author><name sortKey="Pimstone, Sn" sort="Pimstone, Sn" uniqKey="Pimstone S" first="Sn" last="Pimstone">Sn Pimstone</name></author><author><name sortKey="Namdari, R" sort="Namdari, R" uniqKey="Namdari R" first="R" last="Namdari">R. Namdari</name></author><author><name sortKey="Price, N" sort="Price, N" uniqKey="Price N" first="N" last="Price">N. Price</name></author><author><name sortKey="Cohen, C" sort="Cohen, C" uniqKey="Cohen C" first="C" last="Cohen">C. Cohen</name></author><author><name sortKey="Sherrington, Rp" sort="Sherrington, Rp" uniqKey="Sherrington R" first="Rp" last="Sherrington">Rp Sherrington</name></author><author><name sortKey="Hayden, Mr" sort="Hayden, Mr" uniqKey="Hayden M" first="Mr" last="Hayden">Mr Hayden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5BF4208F8F7514ADA3521D4DBA814788C58DD32E</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1399-0004.2012.01942.x</idno><idno type="url">https://api-v5.istex.fr/document/5BF4208F8F7514ADA3521D4DBA814788C58DD32E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000917</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000917</idno><idno type="wicri:Area/Istex/Curation">000917</idno><idno type="wicri:Area/Istex/Checkpoint">000265</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000265</idno><idno type="wicri:doubleKey">0009-9163:2012:Goldberg Y:human:mendelian:pain</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:22845492</idno><idno type="wicri:Area/PubMed/Corpus">000A17</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A17</idno><idno type="wicri:Area/PubMed/Curation">000A17</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A17</idno><idno type="wicri:Area/PubMed/Checkpoint">000A17</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A17</idno><idno type="wicri:Area/Ncbi/Merge">001210</idno><idno type="wicri:Area/Ncbi/Curation">001210</idno><idno type="wicri:Area/Ncbi/Checkpoint">001210</idno><idno type="wicri:Area/Main/Merge">001450</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:12-0366791</idno><idno type="wicri:Area/PascalFrancis/Corpus">000171</idno><idno type="wicri:Area/PascalFrancis/Curation">000A81</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000155</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000155</idno><idno type="wicri:doubleKey">0009-9163:2012:Goldberg Y:human:mendelian:pain</idno><idno type="wicri:Area/Main/Merge">001569</idno><idno type="wicri:Area/Main/Curation">001418</idno><idno type="wicri:Area/Main/Exploration">001418</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Human Mendelian pain disorders: a key to discovery and validation of novel analgesics</title><author><name sortKey="Goldberg, Yp" sort="Goldberg, Yp" uniqKey="Goldberg Y" first="Yp" last="Goldberg">Yp Goldberg</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Development, Xenon Pharmaceuticals Inc, British Columbia, Burnaby</wicri:regionArea><wicri:noRegion>Burnaby</wicri:noRegion></affiliation><affiliation></affiliation><affiliation></affiliation></author><author><name sortKey="Pimstone, Sn" sort="Pimstone, Sn" uniqKey="Pimstone S" first="Sn" last="Pimstone">Sn Pimstone</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Development, Xenon Pharmaceuticals Inc, British Columbia, Burnaby</wicri:regionArea><wicri:noRegion>Burnaby</wicri:noRegion></affiliation></author><author><name sortKey="Namdari, R" sort="Namdari, R" uniqKey="Namdari R" first="R" last="Namdari">R. Namdari</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Development, Xenon Pharmaceuticals Inc, British Columbia, Burnaby</wicri:regionArea><wicri:noRegion>Burnaby</wicri:noRegion></affiliation></author><author><name sortKey="Price, N" sort="Price, N" uniqKey="Price N" first="N" last="Price">N. Price</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Development, Xenon Pharmaceuticals Inc, British Columbia, Burnaby</wicri:regionArea><wicri:noRegion>Burnaby</wicri:noRegion></affiliation></author><author><name sortKey="Cohen, C" sort="Cohen, C" uniqKey="Cohen C" first="C" last="Cohen">C. Cohen</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Development, Xenon Pharmaceuticals Inc, British Columbia, Burnaby</wicri:regionArea><wicri:noRegion>Burnaby</wicri:noRegion></affiliation></author><author><name sortKey="Sherrington, Rp" sort="Sherrington, Rp" uniqKey="Sherrington R" first="Rp" last="Sherrington">Rp Sherrington</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Development, Xenon Pharmaceuticals Inc, British Columbia, Burnaby</wicri:regionArea><wicri:noRegion>Burnaby</wicri:noRegion></affiliation></author><author><name sortKey="Hayden, Mr" sort="Hayden, Mr" uniqKey="Hayden M" first="Mr" last="Hayden">Mr Hayden</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Development, Xenon Pharmaceuticals Inc, Burnaby, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Genetics, University of British Columbia, British Columbia, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Genetics</title><title level="j" type="abbrev">Clin Genet</title><idno type="ISSN">0009-9163</idno><idno type="eISSN">1399-0004</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2012-10">2012-10</date><biblScope unit="volume">82</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="367">367</biblScope><biblScope unit="page" to="373">373</biblScope></imprint><idno type="ISSN">0009-9163</idno></series><idno type="istex">5BF4208F8F7514ADA3521D4DBA814788C58DD32E</idno><idno type="DOI">10.1111/j.1399-0004.2012.01942.x</idno><idno type="ArticleID">CGE1942</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0009-9163</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analgesic</term><term>Analgesics (metabolism)</term><term>Analgesics (therapeutic use)</term><term>Congenital</term><term>Drug Discovery (methods)</term><term>Erythromelalgia</term><term>Erythromelalgia (genetics)</term><term>Genetics</term><term>Human</term><term>Humans</term><term>Mutation (genetics)</term><term>NAV1.7 Voltage-Gated Sodium Channel (genetics)</term><term>NAV1.7 Voltage-Gated Sodium Channel (metabolism)</term><term>Pain</term><term>Pain Insensitivity, Congenital (drug therapy)</term><term>Pain Insensitivity, Congenital (genetics)</term><term>Test validation</term><term>Voltage-Gated Sodium Channel Blockers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>NAV1.7 Voltage-Gated Sodium Channel</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Analgesics</term><term>NAV1.7 Voltage-Gated Sodium Channel</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pain Insensitivity, Congenital</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Erythromelalgia</term><term>Mutation</term><term>Pain Insensitivity, Congenital</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Voltage-Gated Sodium Channel Blockers</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Analgésique</term><term>Congénital</term><term>Douleur</term><term>Erythromélalgie</term><term>Génétique</term><term>Homme</term><term>Validation test</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Génétique</term><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">We have utilized a novel application of human genetics, illuminating the important role that rare genetic disorders can play in the development of novel drugs that may be of relevance for the treatment of both rare and common diseases. By studying a very rare Mendelian disorder of absent pain perception, congenital indifference to pain, we have defined Nav1.7 (endocded by SCN9A) as a critical and novel target for analgesic development. Strong human validation has emerged with SCN9A gain‐of‐function mutations causing inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder, both Mendelian disorder of spontaneous or easily evoked pain. Furthermore, variations in the Nav1.7 channel also modulate pain perception in healthy subjects as well as in painful conditions such as osteoarthritis and Parkinson disease. On the basis of this, we have developed a novel compound (XEN402) that exhibits potent, voltage‐dependent block of Nav1.7. In a small pilot study, we showed that XEN402 blocks Nav1.7 mediated pain associated with IEM thereby demonstrating the use of rare genetic disorders with mutant target channels as a novel approach to rapid proof‐of‐concept. Our approach underscores the critical role that human genetics can play by illuminating novel and critical pathways pertinent for drug discovery.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Goldberg, Yp" sort="Goldberg, Yp" uniqKey="Goldberg Y" first="Yp" last="Goldberg">Yp Goldberg</name></noRegion><name sortKey="Cohen, C" sort="Cohen, C" uniqKey="Cohen C" first="C" last="Cohen">C. Cohen</name><name sortKey="Hayden, Mr" sort="Hayden, Mr" uniqKey="Hayden M" first="Mr" last="Hayden">Mr Hayden</name><name sortKey="Hayden, Mr" sort="Hayden, Mr" uniqKey="Hayden M" first="Mr" last="Hayden">Mr Hayden</name><name sortKey="Namdari, R" sort="Namdari, R" uniqKey="Namdari R" first="R" last="Namdari">R. Namdari</name><name sortKey="Pimstone, Sn" sort="Pimstone, Sn" uniqKey="Pimstone S" first="Sn" last="Pimstone">Sn Pimstone</name><name sortKey="Price, N" sort="Price, N" uniqKey="Price N" first="N" last="Price">N. Price</name><name sortKey="Sherrington, Rp" sort="Sherrington, Rp" uniqKey="Sherrington R" first="Rp" last="Sherrington">Rp Sherrington</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001418 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001418 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5BF4208F8F7514ADA3521D4DBA814788C58DD32E
|texte= Human Mendelian pain disorders: a key to discovery and validation of novel analgesics
}}
| This area was generated with Dilib version V0.6.29. |  |